SCHEMBL5536644

SCHEMBL5536644

Cc1cccc(-c2c(Cl)cc(Cl)cc2Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
ACHE P22303 1/20 0.46
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44
AHR P35869 1/20 0.43
CNR1 P21554 3/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
RAB9A P51151 2/20 0.41
CNR2 P34972 3/20 0.41
HEXA P06865 1/20 0.40
HEXB P07686 1/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12225753 0.80 RXRA (0.50) L3MBTL1ACHEAKR1C2AKR1C1CNR1
SCHEMBL4458179 0.79 ALOX5 (0.48) AHRRAB9ANPC1TSHRSMN1; SMN2
SCHEMBL31236143 0.79 ACHE (0.52) L3MBTL1ACHECNR1RAB9ACNR2
SCHEMBL25014732 0.78 AKR1C2 (0.47) L3MBTL1ACHEAKR1C2AKR1C1CNR1
SCHEMBL23789097 0.78 AKR1C2 (0.47) L3MBTL1ACHEAKR1C2AKR1C1CNR1
SCHEMBL10703217 0.78 DPP4 (0.52) AHRCNR1RAB9ANPC1HPGD
SCHEMBL17033286 0.77 ACHE (0.44) L3MBTL1ACHEAKR1C2AKR1C1CNR1
SCHEMBL5545734 0.77 ESR2 (0.57) ACHEAKR1C2AKR1C1CNR1
SCHEMBL26032118 0.77 ACHE (0.50) L3MBTL1ACHECNR1RAB9ACNR2
SCHEMBL25815477 0.77 AKR1C2 (0.46) L3MBTL1ACHEAKR1C2AKR1C1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 L3MBTL1 1931/4885ACHE 4670/4885AKR1C2 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.